Slide 1: Results Presentation – Q2 & H1 FY22
Results Presentation – Q2 & H1 FY22
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 3: Executive Chairman's Message
Executive Chairman’s Message “Hikal has delivered another quarter of positive performance. From a segmental performance perspective, the Crop Protection business has performed well, registering a positive YoY growth of 105% in Q2 on the back of strong volume growth of our existing products and furth
Slide 4: Quarterly Financial Highlights
Quarterly Financial Highlights
Slide 5: Financial Highlights – Q2 FY22
Financial Highlights – Q2 FY22 Revenue – Q2 FY22 EBITDA – Q2 FY22 EBITDA Margin – Q2 FY22 Rs. 469 Crore Rs. 91 Crore 19.4% YoY QoQ YoY QoQ YoY QoQ 26% 3% 30% -5% 62 bps -158 bps PAT – Q2 FY22 EPS – Q2 FY22 Rs. 44 Crore Rs 3.54 YoY QoQ YoY QoQ 63% -13% 63% -13% © Hikal Limited
Slide 6: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue Performance Highlights +26% • Revenue recorded an increase of 26% YoY 457 469 372 • Higher sales volumes for existing products augmented by addition of new products • Strong performance in both segments - own products as well as CDMO Q2FY21 Q1FY22 Q2FY22 • EB
Slide 7: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue +0.1% Pharmaceuticals - Performance Highlights 279 274 280 • Recorded flat revenue at Rs. 280 Crore as compared to Q2 FY21 • Growth in volumes for several own products • EBIT at Rs 37 Crore, de-growth of 25% YoY • Withdrawal of export incent
Slide 8: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue +105% Crop Protection - Performance Highlights 183 190 • Revenue recorded an increase of 105% YoY • Increased sales volume of existing as well as new products • Efficient pass through of raw material price increase 93 • EBIT of Rs 34 Crore,
Slide 9: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +26% +30% +63% 532 109 51 51 463 457 469 96 44 91 91 40 372 70 27 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Rs. Crore © Hikal Limited
Slide 10: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +0.1% +105% 298 279 269 274 280 235 194 183 190 93 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Pharmaceuticals EBIT Crop Protection EBIT -25% +335% 50 51 48 48 48 37 34 31 32 8 Q2FY21 Q3FY21 Q4FY
Slide 11: Consolidated Profit & Loss – Q2 FY22
Consolidated Profit & Loss – Q2 FY22 Particulars (Rs. Crore) Q2 FY22 Q2 FY21 Y-o-Y Q1 FY22 Q-o-Q Net Sales 469 372 26% 457 3% Expenditure 378 302 361 EBITDA 91 70 30% 96 -5% Margin 19.4% 18.8% 21.0% Other Income 1 1 3 Depreciation 24 21 23 Finance Costs 8 9 8 PBT 60 41 45% 68 -13% Tax 16 14 18 Net P
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets Sep-21 Mar-21 Equities & Liabilities Sep-21 Mar-21 Total Non Current Assets 1129 1,035 Shareholders Fund 1015 933 Property, Plant and Equipment 727 646 Share Capital 25 24 Capital work in Progress 249 245 Other Equity 990 909 Right to Use Assets 65 65 Other Intangib
Slide 13: Cash Flow Statement
Cash Flow Statement Rs. Crore Half Year ended 30-Sep-21 Half Year ended 30-Sep-20 Profit before tax 128 64 Adjustments 67 59 Operating Profit Before Working Capital Changes 195 123 Change in operating assets and liabilities 28 (40) Cash generated from operations 223 83 Income taxes paid 44 17 Net ca
Slide 14: Half-Yearly Financial Highlights
Half-Yearly Financial Highlights
Slide 15: Financial Highlights – Half-Yearly
Financial Highlights – Half-Yearly Revenue – H1FY22 EBITDA – H1FY22 EBITDA Margin – H1FY22 Rs. 926 Crore Rs. 187 Crore 20.2% YoY YoY YoY 28% 53% 328 bps PAT – H1FY22 EPS – H1FY22 Rs. 95 Crore Rs 7.67 YoY YoY 125% 125% © Hikal Limited
Slide 16: Half-Yearly Performance Highlights
Half-Yearly Performance Highlights Revenue EBITDA PAT +28% +53% +125% 926 187 95 725 122 42 H1FY21 H1FY22 H1FY21 H1FY22 H1FY21 H1FY22 Pharmaceuticals Division Crop Protection Division +12% +61% 554 372 493 232 Revenue Revenue H1FY21 H1FY22 H1FY21 H1FY22 +20% +167% 86 66 72 25 EBIT EBIT Rs. Crore H1F
Slide 17: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up 41% 49% 47% 61% 69% 74% 59% 51% 53% 39% 31% 26% H1FY21 FY21 H1FY22 H1FY21 FY21 H1FY22 CDMO Own products CDMO Own products © Hikal Limited
Slide 18: Ratio Analysis
Ratio Analysis ROE ROCE 19.4% 18.1% 15.2% 16.1% 14.5% 15.2% 12.0% 12.8% 12.5% 11.3% 10.7% 11.1% FY17 FY18 FY19 FY20 FY21 H1FY22* FY17 FY18 FY19 FY20 FY21 H1FY22* Net Debt / Equity Net Debt / EBITDA 0.94 0.91 2.9 0.83 2.5 0.71 2.1 2.1 0.61 0.57 1.8 1.6 FY17 FY18 FY19 FY20 FY21 H1FY22 FY17 FY18 FY19 F
Slide 19: Annual Financial Highlights
Annual Financial Highlights
Slide 20: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY21 EBITDA – FY21 EBITDA Margin – FY21 Rs. 1,720 Crore Rs. 323 Crore 18.8% FY17-21 FY17-21 YoY YoY YoY CAGR CAGR 14% 18% 65 bps 14% 13% PAT – FY21 EPS – FY21 Rs. 133 Crore Rs 10.80 FY17-21 FY17-21 YoY YoY CAGR CAGR 58% 58% 19% 19% © Hikal Limited
Slide 21: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT +14% +18% +58% 1,720 323 133 1,507 273 84 FY20 FY21 FY20 FY21 FY20 FY21 Pharmaceuticals Division Crop Protection Division +19% +7% 1,060 620 661 887 Revenue Revenue FY20 FY21 FY20 FY21 +33% +4% 170 100 103 128 EBIT EBIT Rs. Crore FY20 FY21 FY20 FY21 ©
Slide 22: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT +14% +13% 1,720 323 133 1,590 298 1,507 +19% 273 1,300 242 103 197 84 1,034 77 67 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Rs. Crore © Hikal Limited
Slide 23: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue +12% +15% 1,060 651 661 620 939 887 547 753 423 611 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 Pharmaceuticals EBIT Crop Protection EBIT +8% +21% 170 112 100 103 129 128 87 75 99 79 FY17 FY18 FY19 FY20 FY21 FY17 FY18
Slide 24: Sales Break-Up
Sales Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up CDMO CDMO Own products Own products 41.2% 54.0% 69.0% 76.7% 58.8% 46.0% 31.0% 23.3% FY20 FY21 FY20 FY21 © Hikal Limited
Slide 25: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY21 FY20 Y-o-Y Net Sales 1,720 1,507 14% Expenditure 1,397 1,234 EBITDA 323 273 18% Margin 18.8% 18.1% Other Income 5 4 Depreciation 85 82 Finance Costs 36 52 Exceptional Item - 15 PBT 206 127 63% Tax 73 42 Net Profit 133 84 58% Margin
Slide 26: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 21% 19% 14% 24% 22% 18% 19% 17% 20% 19% including DDT 10.80 EPS DPS 8.36 6.85 6.27 5.70 5.18 4.39 3.28 3.35 2.05 2.00 1.20 1.00 1.00 1.20 1.20 1.20 1.20 0.90 0.50 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 ▪ The above dividend is based on Face Value of R
Slide 27: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya +91-9920602034 Kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net www.hikal.com www.sgapl.net © Hikal Limited
Slide 28: HIKAL
HIKAL